10,305 Results
Five-year study shows SRT-100 benefits patients with non-melanoma skin cancer/- Sensus Healthcare
Added 13 hours ago
Sensus Healthcare announced topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation...
FDA approves TransPyloric Shuttle device for obesity.- BAROnova
Added 13 hours ago
BAROnova announced that the FDA has approved the TransPyloric Shuttle (TPS) Device, a non-surgical weight loss solution for adult individuals...
FDA expands approval for KardiaMobile to include bradycardia and tachycardia detection.- AliveCor
Added 13 hours ago
AliveCor announced two additional FDA 510(k)-cleared indications, making KardiaMobile the only consumer ECG device in the world with FDA-clearance to...
From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)
Added 1 day ago
Keytruda and Inlyta approved by FDA to treat first line renal cell carcinoma
Added 1 day ago
Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase...
FDA approves first medical device, Monarch external Trigeminal Nerve Stimulation System to treat ADHD
Added 13 hours ago
The FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called...
Successful COAST-X Phase III study of Taltz for the treatment of non-radiographic axial spondyloarthritis
Added 1 day ago
Eli Lilly and Company announced that Taltz (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase...
Soligenix reports enrollment stage for its pivotal phase III trial of SGX 942 for oral mucositis in head and neck cancer
Added 4 days ago
Soligenix announced that it has reached a significant milestone in the Phase III clinical study (the "DOM-INNATE" study) for SGX...
Results of long term study of tanezumab in patients with osteoarthritis
Added 4 days ago
Pfizer Inc. and Eli Lilly and Company announced top-line results from a Phase III study evaluating tanezumab 2.5 mg and...